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Abstract
Background: Patients with end-stage renal disease (ESRD) and secondary hyperparathyroidism
(SHPT) are at high risk of mortality. Whether an increased risk of death persists after a para-
thyroidectomy (PTX) is not clearly established.
Subjects and methods: The survival of 40 patients with ESRD and SHPT who underwent PTX was
compared with that of 664 ESRD patients.
Results: From first dialysis, a lower mortality rate was found in the group of patients who
underwent PTX than in the nonoperated ESRD group (hazard ratio: 0.23; 95% CI: 0.14–0.37). The
patients who underwent PTX were younger, had a longer time on dialysis, and had a higher
prevalence of kidney transplantation. The mean number of comorbidities was lower (Charlson
score 4.2 ± 2.1 versus 6.4 ± 2.9, p < 0.001). Then, we randomly selected two matched controls
for each PTX case (80 controls, 40 PTX) who had at least an equivalent mean duration of dialysis
between the first dialysis and PTX of the PTX group. In a univariate model, there was a trend for
PTX being associated with prolonged survival. The mortality was higher both among those at an
advanced age and those with a high Charlson score. Adjustments for these covariates made the
effect of PTX no more significant.
Conclusions: The risk of death of patients with severe SHPT leading to PTX differed from that of
nonoperated subjects. The apparent differences in survival may be related to the number and
severity of associated comorbidities. ESRD patients who undergo PTX may represent a subset of
healthier subjects.
Secondary hyperparathyroidism (SHPT) is a commoncomplication of chronic kidney disease (CKD) that
can lead to clinically significant bone disease.1,2 It is also
associated with soft-tissue and vascular calcifications,
cardiovascular disease, and calcifying uremic arteriopa-
thy, all of which may contribute to increased risk of car-
diovascular morbidity and mortality among CKD
patients,3–9 with a relative risk of death between 1.06 and
3.9.
Secondary hyperparathyroidism arises from distur-
bances in calcium, phosphorus, vitamin D, and parathy-
roid hormone metabolism, which develop at an early
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stage of CKD10 and become more prominent as kidney
function declines. To overcome deleterious effects of
SHPT, standard therapies recommended to correct min-
eral metabolism and bone disease include calcium sup-
plementation, dietary phosphorus restriction, phosphate-
binding agents, and/or vitamin D metabolites.1,11 How-
ever, these agents frequently alter the serum levels of
calcium and phosphorus, which result in worsening of
serum values and significant extraskeletal morbidity and
mortality. Calcimimetics, a new class of drugs offer the
possibility to selectively reduce the levels of PTH, serum
calcium, and phosphate at the same time. However,
whether these effects can contribute to improved survival
remains to be demonstrated.1,12 Thus, PTX in patients on
dialysis or in those who have had renal transplants is still
frequently required for the treatment of severe SHPT,
although recent studies have shown that the percentage
of dialysis patients undergoing subtotal or total PTX is
declining,13,14 possibly as a result of more effective
medical management.
Whether PTX modifies the mortality rate among pa-
tients with end-stage renal disease (ESRD) and severe
HPT was studied recently in an observational matched
cohort study using data from the United States Renal
Database System (USRDS). It was shown that PTX pa-
tients displayed prolonged survival during chronic dialy-
sis, with a 15% reduced risk of death. However, an
important limitation of that study is that patient charac-
teristics, in particular comorbidities and cardiovascular
risk factors, were not taken into account in calculating the
risk of death. Indeed, this may potentially explain the
differences in mortality rates.15 The present study was
undertaken to determine whether patients operated on for
SHPT would be at lower risk of premature death, and to
examine whether differences persisted when all comor-
bidities were considered. We thus analyzed survival after
PTX in a well-defined and closely followed cohort of pa-
tients in whom cardiovascular risk factors and comor-
bidities could be carefully recorded and analyzed.
SUBJECTS AND METHODS
Between 1977 and 2002, 741 patients were treated in
our institution for end-stage renal disease. The following
patients were excluded from the analysis: 19 with para-
thyroidectomy following a successful kidney transplant
(tertiary hyperparathyroidism), 13 patients with 3 or more
kidney transplants (9 with a history of parathyroidectomy
and 4 never operated), and 5 whose date of first dialysis
was not known.
A total of 40 patients (18 males, 22 females) with ESRD
and severe hyperparathyroidism underwent PTX be-
tween 1977 and 2002 at the Geneva University Hospital,
a large acute-care teaching hospital that manages 95% of
cases for Geneva and its environs, representing a pop-
ulation of around 400,000. The survival rates of those 40
patients were compared to those of 664 ESRD patients
treated at the same institution during the same period.
Renal failure was due to chronic glomerulonephritis
(n = 13), polycystic kidney disease (n = 9), tubulointer-
stitial nephropathy (n = 12), vascular disease (n = 4),
diabetes (n = 1), or undetermined causes (n = 1). Sev-
enty-three percent (n = 29) were treated with hemodial-
ysis, 10% (n = 4) with continuous ambulatory peritoneal
dialysis, and 18% (n = 7) with the two treatments con-
secutively. This proportional distribution was quite similar
to that of the control group. Mean age at surgery was
47.7 ± 14.7 years (mean ± SD, range: 20–74 years)
and the mean time between the first dialysis and PTX was
5.3 years (95% CI: 0.2–17.5). Initial PTX involved re-
moval of 1 to 3 parathyroid glands (n = 12, 32%); subtotal
PTX (n = 21, 57%), or total PTX with autotransplantation
(n = 4, 10%). Information was not available for 3 patients.
Surgery was undertaken in 1 patient just before the onset
of dialysis; in the other 39 (96%), during the period of
dialysis. Age at first dialysis, gender, and year and date of
surgery were noted for each patient. If the patient died
during the study period, the year and date of death (but
not the main cause of death) were recorded. For each
patient, we retrospectively assessed the number of car-
diovascular disease risk factors. Dyslipidemia, diabetes
and impaired glucose tolerance, hypertension, tobacco
use at any time during the follow-up, obesity, and family
history of cardiovascular disease before the age of 65
years were taken into account. Comorbid conditions,
present at the start of dialysis or that developed during
the follow-up were obtained from the patient records. A
modified Charlson’s Comorbidity Index was computed for
each patient.16 Patients were considered to have a co-
morbid condition if a listed disorder (Table 1) was men-
tioned in his/her medical records, or if the patient had
been treated for it. Four comorbidity groups were estab-
lished: low comorbidity (scores £ 3), moderate comor-
bidity (scores 4 and 5), high comorbidity (scores 6 and 7),
and very high comorbidity (scores ‡ 8).
Statistical analysis
Summary results are given as the mean ± standard
deviation. When the data were not normally distributed,
the summary descriptive statistics were the median and
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interquartile range. Comparisons of continuous variables
between two or more groups were performed with Stu-
dent’s t-test or analysis of variance (ANOVA). When
appropriate, a non-parametric Kruskal-Wallis test was
applied. Chi-square tests were used for comparing pro-
portions. The survival of PTX patients and controls fol-
lowing the first dialysis was quantified using survival
function estimates based on the Kaplan-Meier method.17
Follow-up started on the date of first dialysis and contin-
ued until death or censoring. Censoring events were
survival on 1 March 2003 or at the time of the first suc-
cessful kidney transplant. A kidney transplant was judged
successful if survival of the transplant was longer than 1
year. The resulting observed survival curves were com-
pared using a log-rank test.18 Because of the large age
discrepancy between PTX patients and non-PTX patients
and their relatively small number, it was not possible to
match each PTX case concomitantly for age and duration
of dialysis, or for comorbid conditions. As a result of a
large variation in the duration of dialysis, we randomly
selected two controls for each PTX case who had at least
an equivalent mean duration of dialysis ( ± 2 years),
between the first dialysis and PTX, in order to analyze the
effect of PTX on survival.
A conditional logistic regression was used to estimate
the influence of patient characteristics on the mortality
rate. Independent variables evaluated were gender, age
at first dialysis, number of cardiovascular risk factors,
year when dialysis was started ( ± 10 years), modality of
dialysis (hemodialysis, peritoneal dialysis, or both, at any
time during the follow-up), modified Charlson score, and
parathyroidectomy.
The significance level for two-sided p values was 0.05
in all tests. The data were analyzed using the STATA
statistical software package (version 9.2; Stata Corpora-
tion, College Station, TX).
RESULTS
Patients characteristics
At the time of PTX, 40% of the patients had already
experienced one or more cardiovascular events (coro-
nary artery disease with angina pectoris or myocardial
infarction: 7/40 (18%); cardiac insufficiency: 7/40 (18%);
acute stroke: 3/40 (8%); or cardiac arrhythmia disorders:
2/40 (5%)). About half the patients (58%) had symptom-
atic SHPT, with diffuse bone or joint pains (17/40, 43%),
general symptoms (fatigue, muscle weakness, anorexia,
3/40, 8%), neuropsychological disorders (1/40, 3%), and/
or pruritus (2/40, 5%). Three patients (8%) had experi-
enced a low trauma fracture and 10 (25%) were clearly
identified by dual-energy x-ray absorptiometry as having
osteoporosis. Osteitis fibrosa was diagnosed based on
radiologic examination of 11 patients. The main cause of
surgical referral was refractory hypercalcemia (n = 29;
73% patients) or hyperphosphatemia (n = 23; 58% of the
patients). Data on serum PTH levels were available for 28
patients before surgery. The mean serum PTH level was
19 ± 15 times the upper limit of the normal range.
The patients who underwent parathyroid surgery for
secondary hyperparathyroidism had different character-
istics from those of the control group (Table 2). The pri-
mary causes of end-stage renal failure were different.
The most significant differences were younger age at first
dialysis, a longer period of dialysis, and a higher preva-
lence of kidney transplantation, even with unsuccessful
outcome, but a lower mean number of comorbidities.
Cardiovascular risk factors and dialysis modalities did not
differ between the two groups.
Survival rate
Only one PTX patient died within one year of surgery.
Using survival function estimates based on the Kaplan-
Table 1.














Moderate or severe renal disease
Diabetes with end-organ damage2
Any tumor, leukemia, lymphoma
3 Moderate or severe
liver disease
6 Metastatic solid tumor
AIDS
1In addition, for each decade > 40 years of age, a score of 1
was added to the comorbidity score.
2Nondiabetic patients received a minimum score of 2 for
moderate to severe renal disease, and diabetic patients re-
ceived a minimum of 4 (2 for diabetic end-organ damage and 2
for end-stage renal disease)
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Meier method, it was found that the mortality rate after the
first dialysis was significantly lower in the PTX group
(hazard ratio: 0.23; 95% CI: 0.14–0.37) (Fig. 1). Because
of the differences between the two populations (Table 2),
we tried specifically to evaluate the influence of PTX on
survival. We randomly selected two controls for each PTX
case, who had at least an equivalent mean duration of
dialysis, between the first dialysis and PTX for the PTX
group and the beginning of dialysis and any censoring
event in the control group ( ± 2 years) to analyze the
effect of PTX on survival (40 PTX patients and 80 con-
trols) Some differences were still present after this
matching: younger age at time of first dialysis, a lower
number of comorbidities, and a higher number of renal
transplantations (Table 3). The censoring at time of renal
transplantation alleviated the confounding effect of
transplantation on survival. Then, conditional logistic
regression was used to estimate the influence of patient
characteristics on the mortality rate. Independent vari-
ables evaluated were gender, age at first dialysis, number
of cardiovascular risk factors, year of initiation of dialysis
Table 2.
Patients’ characteristics for the whole population
Dialyzed patients without PTX
(n = 664)
Dialyzed patients with PTX
(n = 40)
P
N (%) Mean ± SD min max N (%) Mean ± SD min max
Gender N (% of male) 391 (59) 18 (45) 0.060
Cause of renal failure
Chronic glomerulonephritis 159 (24) 13 (33) 0.151
Polycystic kidney disease 62 (9) 9 (23) 0.014
Vascular 199 (30) 4 (10) 0.001
Tubulointerstitial 117 (18) 12 (30) 0.045
Diabetes 113 (17) 1 (3) 0.001
Other or unknown 74 (11) 1 (3) 0.059
Age at first dialysis 57.2 ± 17.1 11 90 42.6 ± 15.2 14 69 0.001
Modality of dialysis 0.708
Hemodialysis 509 (77) 29 (73)
Peritoneal dialysis 52 (8) 4 (10)
Both modalities 103 (16) 7 (18)
Time on dialysis (years) 2.9 ± 3.3 0 28 10.2 ± 7.2 0 28 0.001
Renal graft (%) 252 (38) 22 (55) 0.025
Number of renal transplantations (RT) 0.005
Never 411 (62) 18 (45)
One RT 221 (33) 15 (38)
Two RT 32 (5) 7 (18)
Functioning renal graft (%) 213 (32) 15 (38) 0.291
Mean number of cardiovascular risk factors 1.4 ± 0.9 0 3 1.4 ± 1.0 0 3 0.882
Mean modified Charlson score 6.4 ± 2.9 2 17 4.2 ± 2.1 2 17 0.001
Charlson score
Low score ( £ 3) 123 (19) 18 (45)
Moderate score (4 or 5) 143 (22) 13 (33)
High score (6 or 7) 167 (25) 7 (18)
Very high score ( ‡ 8) 231 (35) 2 (5) 0.001
Figure 1. Survival after first dialysis. Kaplan-Meier survival
estimates for 40 PTX patients and 664 nonoperated patients
with ESRD. Follow-up started on the date of first dialysis, and
continued until death or censoring. Censoring took place at
survival on 1 March 2003 or first successful kidney trans-
plantation. A kidney transplantation was judged successful if
survival of the transplant was greater than one year.
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( ± 10 years), modality of dialysis (hemodialysis, perito-
neal dialysis, or both, at any time during the follow-up),
modified Charlson score, and parathyroidectomy.
In a univariate model, there was a trend for PTX being
associated with prolonged survival (Fig. 2, Table 4). The
mortality rate was higher with advanced age at first dial-
ysis and high modified Charlson score. To evaluate to
what extent these covariates could affect survival, inde-
pendent variables were included in a multivariate model.
Adjustments for these covariates made the effect of PTX
not any more significant (Table 4). The age at first dial-
ysis, the year of first dialysis after 1990, and a highly
modified Charlson score were significant and indepen-
dent predictors of death.
DISCUSSION
Patients with ESRD are at high risk of cardiovascular
morbidity and mortality, particularly from ischemic heart
disease and heart failure.19 Secondary hyperparathy-
roidism is believed to contribute to an increased risk of
cardiovascular mortality, but the direct link between PTH
and disorders of cardiovascular structure and function in
Table 3.
Patient characteristics (matched case-control study)
Dialyzed patients with no PTX
(n = 80)
Dialyzed patients with PTX
(n = 40)
P Value
N (%) Mean ± SD min max N (%) Mean ± SD min max
Gender N (% of male) 41 (51) 18 (45) 0.326
Cause of renal failure
Chronic glomerulonephritis 26 (33) 13 (33) 0.579
Polycystic kidney disease 9 (11) 9 (23) 0.090
Vascular 17 (21) 4 (10) 0.099
Tubulointerstitial 22 (28) 12 (30) 0.467
Diabetes 5 (6) 1 (3) 0.346
Other or unknown 7 (9) 1 (3) 0.186
Age at first dialysis 55.0 ± 14.6 26 88 42.6 ± 15.2 14 69 0.001
Modality of dialysis 0.310
Hemodialysis 65 (81) 29 (73)
Peritoneal dialysis 3 (4) 4 (10)
Both modalities 12(15) 7 (18)
Time on dialysis (years) 8.4 ± 4.7 0 28 9.6 ± 6.9 1 28 0.275
Renal graft (%) 21 (26) 22 (55) 0.002
Number of renal transplants (RT) 0.004
Never 59 (74) 18 (45)
One RT 17 (21) 15 (38)
Two RT 4 (5) 7 (18)
Functioning renal graft (%) 20 (25) 15 (38) 0.114
Mean number of cardiovascular risk factors 1.4 ± 1.0 0 3 1.2 ± 0.9 0 3 0.298
Mean modified Charlson score 6.0 ± 2.6 2 16 4.2 ± 1.6 2 13 0.001
Charlson score 0.001
Low score (£ 3) 14 (18) 18 (45)
Moderate score (4 or 5) 19 (24) 13 (33)
High score (6 or 7) 27 (34) 7 (18)
Very high score ( ‡ 8) 20 (25) 2 (5)
Figure 2. Survival after PTX. We randomly selected two
controls for each PTX case who had an equivalent mean
duration of dialysis, between the first dialysis and PTX for the
PTX group and the beginning of dialysis and any censoring
event for the control group (plus or minus 2 years) to analyse the
effect of PTX on survival.
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ESRD is not fully understood. The deleterious effects of
high PTH levels in ESRD might be related to an increase
in cell calcium content. Previous studies have suggested
that high levels of PTH are associated with impaired
ventricular diastolic and systolic function.20–24 Secondary
hyperparathyroidism is also associated with left ventric-
ular hypertrophy.25–29 In combination with the higher
prevalence of hypertension, this could contribute to the
greater prevalence of congestive heart failure in SHPT
patients. Several studies have suggested that hyperlipe-
mia in renal failure is related to elevated PTH levels.30–32
Decreased PTH-related insulin sensitivity may also aug-
ment atherosclerotic changes.33 Myocardial disease,
along with atherosclerosis of the coronary arteries,34 may
increase the risk of myocardial infarction and arrhyth-
mias, which could contribute to sudden death, and thus to
higher mortality rates among ESRD patients.
Whether PTX reduces the risk of premature death of
patients with ESRD and severe SHPT is not clearly ac-
cepted because data on the influence of PTX in ESRD on
survival are very scarce. A beneficial effect was sug-
gested in a recently published report.15 Long-term post-
PTX survival improved, with a relative hazard ratio for
mortality of 0.85 (95% CI: 0.78–0.92) after one year. A
higher short-term mortality rate was also indicated in the
first 30 days after surgery.
It has been demonstrated that PTX leads to a statisti-
cally and clinically significant decrease in blood pressure
levels.35–37 However, these data were not confirmed by
others groups.38,39 Another recent study has demon-
strated that left ventricular function in patients with ad-
vanced SHPT and dilated cardiomyopathy markedly
improved following PTX.40 Goldsmith et al. noted reduced
progression of calcification in haemodialysis patients who
underwent PTX.41
Our own study suggested that the survival rate of pa-
tients who develop severe SHPT leading to PTX may
differ from that of nonoperated subjects. Indeed, in a first
step, we analyzed survival after the first dialysis of all the
patients in the study. Mortality was significantly lower in
the PTX group, but the patient characteristics were
markedly different. We then selected a control group that
was more comparable to the PTX patients. The only dif-
ferences that persisted after matching were age at first
dialysis and the modified Charlson morbidity score.
Parathyroidectomy patients were younger at first dialysis
and had fewer comorbidities. The small number of pa-
tients and adjustments for these covariates made the
effect of PTX nonsignificant.
It is unlikely that the population had a selection bias, as
all cases of SHPT in Geneva are managed at our insti-
tution. Thus, patients selected for surgery are more likely
to have had advanced disease with symptoms than those
selected for conservative management, most of whom
had asymptomatic disease with a lower risk prevalence of
comorbidity. Nevertheless, some patients may have been
in too poor a condition to tolerate surgery, and this would
mean that the risk of death for some of those who were
managed conservatively might have been higher than for
those undergoing surgery.
Table 4.
Factors influencing mortality rate in patients with end-stage renal disease
Unadjusted OR (95% CI) p R2 Adjusted OR (95% CI) p R2
PTX 0.54 (0.24–1.17) 0.117 0.017 1.50 (0.49–4.61) 0.478
Mean N of cardiovascular risk factors 0.95 (0.64–1.41) 0.789 0.001 1.06 (0.60–1.88) 0.845
Gender 1.15 (0.55–2.40) 0.704 0.001 .869 (0.30–2.53) 0.797
Age at first dialysis 1.08 (1.05–1.12) 0.001 0.208 1.09 (1.03–1.15) 0.003
Modality of dialysis 0.5244 0.009
Hemodialysis
Peritoneal dialysis 2.19 (0.41–11.51) 0.357 2.50 (0.24–26.31) 0.445
Both modalities 1.48 (0.53–4.13) 0.453 1.79 (0.40–7.96) 0.447
Charlson score 0.001 0.228
Low score (£ 3)
Moderate score (4 or 5) 2.03 (0.67–6.18) 0.213 0.863 (0.20–3.74) 0.844
High score (6 or 7) 5.03 (1.69–14.98) 0.004 1.37 (0.23– 8.11) 0.731
Very high score (‡ 8) 62.66 (7.12–551.47) 0.001 44.50 (2.44–811.22) 0.010
Years of first dialysis 0.480 0.001
1970
1980 1.42 (0.56–3.58) 0.457 0.80 (0.23–2.76) 0.730
1990 0.827 (0.30–2.24) 0.709 0.06 (0.01–0.38) 0.003
0.39*
*Whole model.
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The low number of patients and deaths could have
limited our ability to detect an effect on survival. This was
compensated by the fact that a homogeneous population
was studied, with consistent and homogeneous data
collection. Finally, the study was performed during the
period (1977 to 2002) before new, less-hypercalcemic
active vitamin D analogs (such as paricalcitol) and se-
velamer became available. It is therefore improbable that
survival was altered by modification of treatment strate-
gies. These results could also suggest that PTX should
be performed earlier, before these comorbidities develop.
But, as serum PTH levels were not analyzed, this
assumption remains hypothetical.
In conclusion, we found that the risk of death of patients
who developed severe SHPT leading to PTX was differ-
ent from that of nonoperated subjects. But this apparent
difference may be related to the number and severity of
associated comorbidities. Thus, ESRD patients who un-
dergo PTX may represent a subset of possibly healthier
subjects than those not undergoing PTX.
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